Following a gut molecule toward the brain

# Following a gut molecule toward the brain OCTOBER 11, 2026 A molecule made by bacteria in the gut may be tied to how fast the brain ages. In a study of 1,196 adults with no cognitive impairment, people with higher blood levels of imidazole propionate, or ImP, scored lower on memory and thinking tests and showed more blood markers linked to Alzheimer's disease. The route from the gut to the brain is becoming more chemically specific. Imidazole propionate is one candidate worth following, with human associations and laboratory experiments beginning to describe different parts of the same question. The study, published in Nature Communications in 2026, combines several kinds of evidence. The human part is observational. It followed adults from the Wisconsin Alzheimer's Disease Research Center and the Wisconsin Registry for Alzheimer's Prevention, with an average age of 61.2 years. Observational work can show links. It cannot prove that one thing causes another. The team also ran experiments in mice and in cells grown in the lab, and used a genetic analysis to probe cause. ImP is made when certain gut bacteria break down histidine, an amino acid, without using oxygen. The bacteria need an enzyme called urocanate reductase to do this. According to the paper, higher blood ImP has already been linked to type 2 diabetes, high blood pressure, atherosclerosis and chronic kidney disease. Until now, its effect on the brain had been largely unexplored. In the people studied, higher ImP went with lower scores on a preclinical Alzheimer's cognitive composite, a set of tests designed to catch early change. The authors adjusted for age, sex, body mass index and APOE ε4 status, a well-known genetic risk factor. Plasma ImP was higher in older people and in men. Heart and metabolic health did not fully explain the link. The researchers used a score of lifestyle-related dementia risk factors, including obesity, smoking, diabetes and high blood pressure. ImP was higher in people with higher scores. In a mediation analysis, only 13-16% of the indirect effect ran through ImP between that risk score and the cognitive results. When the score was added as an adjustment, ImP remained the main contributor to the association. The authors conclude that ImP acts largely as an independent factor rather than working indirectly through other conditions. Cognitive change over time pointed the same way. The team compared people in the highest and lowest quarters of ImP levels. The high group had lower starting scores and a steeper decline with age. On an animal-naming test, for example, the high group started lower and declined faster. Similar patterns appeared on letter fluency and a trail-making test. The authors say the gap widened over time. Blood markers of brain injury fit that picture. Higher plasma ImP was associated with higher plasma neurofilament light chain, a marker of nerve cell damage, and with higher plasma pTau-217, a marker of Alzheimer's-type tau changes. In 224 people with spinal fluid samples, plasma ImP was also linked to neurofilament light chain in that fluid, though the correlation was modest (R = 0.2). A marker of astrocyte activation, a type of brain support cell, showed only a trend. Not every result was clean. Brain scans of glucose use showed no overall link to ImP in 168 people. A signal in the frontal lobes of 51 men disappeared when one high-ImP outlier was left out. And the pTau-217 pattern over time was mixed: the high-ImP group started higher but rose slightly more slowly, which the authors read as a possible plateau. The cause question is where the genetics and animal work come in. The researchers found a region on chromosome 12 tied to both plasma ImP levels and Alzheimer's risk. They say this supports a role for the body's own genes in setting ImP levels, and a causal role for the molecule in Alzheimer's. This is the authors' interpretation, and it is the weakest link in the argument. In mice, long-term ImP treatment worsened Alzheimer's-like pathology. In cultured brain cells, ImP weakened the barrier formed by brain blood vessel cells and increased tau hyperphosphorylation, a chemical change tied to tau tangles. That effect was blocked by inhibiting an enzyme called GSK-3β. These are lab and animal findings, and they may not carry over to people. The coverage went further in places. ScienceDaily, relaying a University of Wisconsin-Madison release, quoted Bendlin comparing a possible ImP-lowering drug to a statin. The paper itself is more careful: it says targeting ImP "may represent a potential strategy." The release also said about 43% of participants carried the genetic variant tied to higher ImP, and quoted researcher Federico Rey saying the variant's link to Alzheimer's risk may now be explained. Those points come from the coverage, not the passages of the paper available to us. So what does this mean for daily life? Not much yet. Histidine is found in many protein-rich foods and is essential to humans. Study co-leader Barbara Bendlin told ScienceDaily that avoiding eggs or red meat is not the answer, because "you need histidine, and it's all over the place." Diet has not been tested as a way to lower ImP or dementia risk here. The study did not test whether lowering ImP in people protects the brain. WHAT TO WATCH NEXT Whether other groups confirm the link in more varied populations, whether a reliable ImP blood test emerges, and whether any drug that lowers ImP is shown to slow cognitive decline in a human trial. A useful next step would connect those parts without skipping the human intervention study. A molecule can be a compelling lead long before it becomes a treatment. Sources: Nature communications (2026), ScienceDaily (University of Wisconsin-Madison, Nature Communications) Nature communications (2026): https://doi.org/10.1038/s41467-026-74744-z ScienceDaily (University of Wisconsin-Madison, Nature: https://www.sciencedaily.com/releases/2026/09/260930225459.htm ---